What does the 2022 EU GMP Annex 1 change for sterile batch records and review?
By Savi C., Co-Founder · Published Nov 16, 2026
What changed and when
Annex 1 covers the manufacture of sterile medicinal products. The 2022 revision replaced the previous version with a much longer document built around quality risk management and a contamination control strategy, or CCS. It came into operation on August 25, 2023, one year after publication, and point 8.123 came into operation on August 25, 2024. PIC/S brought the same text into its GMP Guide, PE 009-17, on August 25, 2023, with some minor differences.
Much of the revision concerns premises, cleanrooms, barrier technology and personnel. For the batch record and its review, the change is that Annex 1 now says, in numbered points, what has to be in the record and what has to be reviewed before a batch is certified or released.
Annex 1 points that land in the batch record or release review
Point
3.1(vii)
What it asks for
People certifying or releasing sterile products have access to the manufacturing and quality information they need, and the knowledge to judge it
Point
3.2
What it asks for
Non-conformities such as sterility test failures, environmental monitoring excursions and procedural deviations are investigated before certification or release, with the scope of batches covered justified
Point
6.12
What it asks for
After water system sanitisation, microbiological and endotoxin results are verified and approved before batches made with that water are considered for release
Point
6.19
What it asks for
Gas filters used per batch, or as product vessel vent filters, are integrity tested and the results reviewed as part of release
Point
8.17
What it asks for
Every intervention and line stoppage is recorded in the batch record with its time, duration and the operators involved
Point
8.33
What it asks for
Visual inspection results are recorded, and defect types and numbers trended
Point
8.45
What it asks for
Each sterilisation run has a record and a unique identifier, and its conformity is reviewed and approved as part of release
Point
8.86
What it asks for
Critical filtration parameters, including filtration time for a known volume and pressure difference, are in the batch record
Point
8.87
What it asks for
Sterilising grade filters are integrity tested after use, and before use after sterilisation (PUPSIT), or by an alternative approach backed by a thorough risk assessment where PUPSIT is not possible
Point
8.124
What it asks for
Lyophilizer filter integrity test results are part of release
Point
9.3 and 10.10
What it asks for
Environmental and process monitoring information, including trend data for classified areas, is reviewed as part of release
Additions to a sterile batch review checklist
During the batch
- Each intervention is recorded with time, duration and operators, and matched to the list of qualified interventions
- Any non-qualified intervention has been assessed by the quality unit before disposition
- Filtration time, pressure difference and filter integrity results are in the record and inside validated limits
- Glove integrity checks, where isolators are used, were done at the frequency your procedure sets
Supporting records
- Every sterilisation cycle used for the batch is identified by its unique cycle number and its record approved
- Where lyophilizers are loaded by hand with no barrier separation, they were sterilised before the load, as 8.123 expects
- Water and gas results for the batch period were approved before release
Monitoring and investigations
- Environmental and personnel monitoring for the batch period was reviewed, including trends, not only single results
- For short shelf-life products where data is not yet complete, the most recent available data was reviewed
- Every excursion or deviation is investigated, with the reason other batches were included or excluded recorded
The CCS as the reviewer’s reference
Point 2.3 requires a CCS across the facility that defines all critical control points and assesses the effectiveness of every control and monitoring measure. Point 2.5 lists what it should consider, including process risk management, sterilisation validation, monitoring systems and prevention mechanisms such as trend analysis and CAPA.
For batch review, the CCS is what turns a list of checks into a judgement. It tells the reviewer which controls are critical for this product and line, so an intervention, a monitoring result or a filter test can be weighed against the risk it was meant to control. Annex 1 also says frequencies such as lyophilizer sterilisation for automated or closed barrier loading should be justified in the CCS, so review should check against what the CCS says.
How Litewave fits
Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from. For sterile products that can include intervention entries, filtration parameters and the cross-references to sterilisation and monitoring records that Annex 1 puts in scope. Litewave proposes, qualified people approve, and certification stays with your Qualified Person.
Questions we get asked
Does Annex 1 apply to products made for the US market?
Annex 1 is EU GMP guidance, and PIC/S uses the same text. FDA has its own guidance on sterile drug products produced by aseptic processing. A site supplying the EU or a PIC/S member market is inspected against Annex 1 whatever else it supplies.
Does Annex 1 apply to non-sterile products?
Not as a requirement. Its scope says some principles, such as the CCS, cleanroom classification and monitoring, may be used for non-sterile products where contamination control matters. A manufacturer that does so should document which principles it applies.
What does point 8.123 require?
That lyophilizers and their transfer and loading areas are designed to minimise operator intervention, that sterilisation frequency is based on design and risk, and that manually loaded or unloaded lyophilizers with no barrier separation are sterilised before each load. It came into operation on August 25, 2024.
